612499-04-4

Basic information

• Product Name: 5-BROMOTHIOPHEN-2-YLMETHYLAMINE
• Synonyms: CHEMBRDG-BB 4191314;C-(5-BROMO-THIOPHEN-2-YL)-METHYLAMINE;5-BROMOTHIOPHEN-2-YLMETHYLAMINE;RARECHEM AL BW 2382;2-Thiophenemethanamine, 5-bromo-;1-(5-bromo-2-thienyl)methanamine(SALTDATA: HCl);1-(5-bromo-2-thienyl)methanamine 1HCl;1-(5-broMothiophen-2-yl)MethanaMine
• CAS NO: 612499-04-4
• Molecular Formula: C₅H₆BrNS
• Molecular Weight: 192.08
• Mol File: 612499-04-4.mol

Chemical Properties

• Boiling Point: 246.1 °C at 760 mmHg
• Flash Point: 102.6 °C
• Appearance: /
• Density: 1.669 g/cm³
• Vapor Pressure: 0.0277mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: 2-8°C
• PKA: 8.36±0.29(Predicted)
• CAS DataBase Reference: 5-BROMOTHIOPHEN-2-YLMETHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMOTHIOPHEN-2-YLMETHYLAMINE(612499-04-4)
• EPA Substance Registry System: 5-BROMOTHIOPHEN-2-YLMETHYLAMINE(612499-04-4)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 612499-04-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromothiophen-2-ylmethylamine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications. Its unique structure allows for the creation of molecules with specific biological activities, enhancing the effectiveness of medications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromothiophen-2-ylmethylamine is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these products can lead to the development of more effective and targeted agricultural solutions to protect crops and enhance yield.
Used in Organic Material Synthesis:
5-Bromothiophen-2-ylmethylamine is employed as a key component in the synthesis of organic materials, including polymers and other specialty chemicals. Its unique properties allow for the creation of materials with specific characteristics, such as improved stability, reactivity, or selectivity in various applications.
Used in Chemical Reactions as a Building Block:
In the broader chemical industry, 5-Bromothiophen-2-ylmethylamine serves as a versatile building block for a wide range of chemical reactions. Its reactivity and structural features make it suitable for use in the synthesis of complex organic compounds, contributing to the advancement of chemical research and development.
Overall, 5-Bromothiophen-2-ylmethylamine's diverse applications across different industries highlight its importance as a chemical compound with significant potential in various fields, from healthcare to agriculture and material science.

InChI:InChI=1/C5H6BrNS/c6-5-2-1-4(3-7)8-5/h1-2H,3,7H2

Upstream product

• 215183-27-0 tert-butyl ((5-bromothiophen-2-yl)methyl)carbamate 
• 2160-62-5 5-bromo-2-thiophenecarbonitrile 
• 4701-17-1 5-bromo-2-thiophencarboxaldehyde 
• 32316-92-0 naphthalene-2-boronic acid 
• 1003-31-2 thiophene-2-carbonitrile 
• 401485-19-6 tert-butyl N-(thiophen-2-ylmethyl)carbamate 
• 27757-85-3 2-Aminomethylthiophene 
• 79387-71-6 (5-bromothien-2-yl)methanol 
• 176441-92-2 2-(2'-bromothien-5'-ylmethyl)phthalimide 

Downstream Products

• 933990-53-5 di-(hydroxymethyl)-(5-bromothiophene-2-yl)anamine 
• 849805-56-7 2-amino-N-(5-bromo-thiophen-2-ylmethyl)-6-methoxymethyl-nicotinamide 
• 917081-50-6 2-bromo-5-aminomethyl-thiophene trifluoroacetate 
• 1134203-19-2 N-(5-bromo-thiophen-2-ylmethyl)-2-trifluoromethyl-benzenesulfonamide 
• 1134203-27-2 N-(5-bromo-thiophen-2-ylmethyl)-2-chloro-benzenesulfonamide 
• 1184230-65-6 C₂₅H₂₀BrNOS 
• 1706525-09-8 N⁶-[(5-bromothiophen-2-yl)methyl]adenosine 
• 215183-27-0 tert-butyl ((5-bromothiophen-2-yl)methyl)carbamate 
• 4701-17-1 5-bromo-2-thiophencarboxaldehyde 

Relevant articles and documents

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Novel quinazoline EGFR inhibitor, and preparation method and application thereof

A novel quinazoline EGFR inhibitor, and a preparation and an application thereof belong to the field of synthesis of medicines. The novel quinazoline EGFR inhibitor has a general formula shown in thedescription; and in the general formula, R is one from H, F, Cl, Br, and I, and R1 and R2 are same to or different from each other, and are respectively selected from H, a nitro group, an amino group,a hydroxyl group, a 2-methoxyethoxy group, a C1-C4 alkoxy group and a C1-C4 alkyl group. The novel quinazoline EGFR inhibitor is different from existing quinazoline inhibitors with the 4-position substituted with various anilines, and is designed and synthesized by substituting the 4-position of a quinazoline skeleton with a broadly bioactive thienylmethylamine and reasonably modifying the 6-position and the 7-position with groups not including an electrophilic acrylamide bond in order to avoid covalent bonds with EGFR. Compared with existing antitumor drugs, the above compound can significantly inhibit EGFR phosphorylation, and has excellent anti-proliferative activity against EGFR overexpressing tumor cells (such as A431 and MCF-7).

Synthesis and biological evaluation of some novel thiophene-bearing quinazoline derivatives as EGFR inhibitors

Background: With the approval of gefitinib, erlotinib, afatinib, and osimertinib for clinical use, targeting Epidermal Growth Factor Receptor (EGFR) has been intensively pursued. Similar to most therapies, challenges related to the treatment resistance against these drugs have emerged over time, so new EGFR Tyrosine Kinase Inhibitors (TKIs) need to be developed. This study aimed to investigate the potential use of a series of thiophene-bearing quinazoline derivatives as EGFR inhibitors. We designed and synthesized nine quinazolin derivatives, among which five compounds (5e, 5f, 5g, 5h, and 5i) were reported for the first time. Methods: Two cancer cell lines, A431 (overexpressing EGFR) and A549 (EGFR wild-type and K-ras mutation), were treated by these compounds and subjected to MTT assay. The A431 cells were selected for further treatment (5e) and Western blot analysis. Results: Although the compounds exerted no obvious effects on the proliferation of A549 cells, seven out of the nine compounds significantly inhibited the growth of A431 cells. In particular, the IC50 values of 5e and erlotinib were nearly equal. Western blot results showed that 5e significantly inhibited EGFR autophosphorylation in A431 cells. Structure-activity relationships indicated that quinazolines bearing 6,7-side chains were more potent than those unsubstituted at the 6,7-positions. Moreover, electron-withdrawing hydrophobic groups on the 5-position of the thiophene were preferred, such as chlorine or bromine atom. Conclusion: Nine 4-aminoquinazolin derivatives were designed, synthesized, and evaluated against A431 and A549 cell lines. Seven compounds significantly inhibited the growth of A431 cells. In particular, 5e possessed similar antitumor potency to that of erlotinib.

Heterocyclic compound with Wnt signal path inhibitory activity and application thereof

The invention provides a heterocyclic compound with Wnt signal path inhibitory activity. The heterocyclic compound and chemically acceptable salt, isotope, isomer and a crystal structure thereof are provided with a structure shown as the general formula I (see the formula in the description). The invention further provides application of the heterocyclic compound with the Wnt signal path inhibitory activity. The heterocyclic compound with the Wnt signal path inhibitory activity serves as effective antagonist of a Wnt signal path, and can be used for treating or preventing diseases caused by abnormity of the Wnt signal path.

Assembling p-type molecules on single wall carbon nanotubes for photovoltaic devices

We report the design and synthesis of an oligothiophene molecule that noncovalently functionalizes carbon nanotubes to create a hybrid material for photovoltaic devices.

NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND

Disclosed is an antimalarial agent containing a compound represented by the formula: [wherein A1 represents a 3-pyridyl group that may have a substituent, a 6-quinolyl group that may have a substituent, or the like; X1 represents a group represented by the formula -C(=O)-NH- or the like; E represents a furyl group, a thienyl group or a phenyl group; with the proviso that A1 may have one to three substituents, and E has one of two substituents] or a salt thereof or hydrates thereof.

HYDANTOIN DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISORDERS

This invention relates to compounds of the Formula: (I); or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α or combinations thereof.

NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND

The present invention provides an antifungal agent represented by the formula: [wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula -NH-C(=O)-, a group represented by the formula -C(=O)-NH-, or the like; E represents a furyl group, a thienyl group, a pyrrolyl group, a phenyl group, a pyridyl group, a tetrazolyl group, a thiazolyl group or a pyrazolyl group; with the proviso that A1 may have 1 to 3 substituents, and E has one or two substituents].

PYRAZOLE DERIVATES AS CANNABINOID RECEPTOR MODULATORS

Compounds of formula (I), are cannabinoid CB1 receptors, useful, inter alia in the treatment of obesity: (I) wherein A1 is hydrogen, -COOH, or tetrazolyl, and A2 is hydrogen, -COOH, tetrazolyl, -CN, -CF3, -COR6, -SO2R6, -OR7, -NR7R8, -NHCOR6, and -NR7SO2R8 provided that one of A1 and A2 is either -COOH or tetrazolyl; p is O or 1 and A3 is phenyl or cycloalkyl, either of which is optionally substituted with R4 and/or R5; q is O or 1 ; R1 is a bond, or - (CH2)aB1(CH2)b- wherein a and b are independently O, 1 , 2 or 3 provided that a+b is not greater than 4, and B1 is -CO-, -0-, -S-, -SO-, -SO2-, -CH2-, -CHOH- or -NR7-; R2 is a bond, -(CH2)aB1 (CH2)b- or -[(CH2)aB1 (CH2)b]n-A4-[(CH2)cB2(CH2)d]m- wherein a, b, and B1 are as defined for R1; B2 is as defined for B1, c and d are independently 0,1 , 2 or 3; with the proviso that a+b+c+d is not greater than 6, n and m are independently O or 1 and A4 is a monocarbocyclic or monoheterocyclic ring, having 3 to 8 ring atoms, optionally substituted with one or more of -F, -Cl, -Br, -CN, -CF3, C1-C4 alkyl, cycloalkyl, -OR9, oxo or -NR7R8; R3 is hydrogen, C1-C4 alkyl, cycloalkyl, -CF3, -OR9, -NR7R8, -(CH2)SCOR6, -(CH2)SSO2R6, -(CH2)SNR7COR6, -(CH2)SNR7COOR8, -(CH2)SNR7SO2R6, wherein s is 1 , 2, 3 or 4; R4 and R5 independently -R9, -CN, -F, -Cl, -Br, -OR9, -NR7R8, -NR7COR6, -NR7SO2R6, -COR6, -SR9, -SOR9, -SO2R6, (C1-C4 alkyl)OR9, -(C1-C4 alkyl)NR7R8, -(C1-C4 alkyl)NR7COR6, C1-C4 alkyl)NR7COOR8, -(C1-C4 alkyl)NR7SO2R6, -(C1-C4 alkyl)COR6, -(C1-C4 alkyl)SO2R6, -NR7COOR8, or [N-(C1-C4 alkyl)]- tetrazolyl; R6 is C1-C4 alkyl, cycloalkyl, -CF3 or -NR7R8; R7 and R8 are independently hydrogen, C1-C4 alkyl or cycloalkyl and R9 is hydrogen, C1-C4 alkyl, cycloalkyl, fully or partially fluorinated C1-C4 alkyl.